The Indian Competition Authority clears structural separation of global pharmaceutical company's bioscience business into separate new pharmaceutical company (Baxter India / Baxalta India)

Sharma, Man Mohan

Previous article The Chinese Ministry of Commerce fines several undertakings for breaches of merger notification rules (FJEI / FPID) (Nanjing Puzhen / Bombardier Sweden) (BestTv / Microsoft) Next article The UK Competition Authority orders licensing remedy to meet concerns over horizontal unilateral effects resulting from a merger in the personal lubricants market (Reckitt Benckiser / Johnson & Johnson)

8 Sep 2015

The Indian Competition Authority clears structural separation of global pharmaceutical company’s bioscience business into separate new pharmaceutical company (Baxter India / Baxalta India)

KEYWORDS

Reference

Competition Commission of India, Combination Registration No. C-2015/07/297, Baxter India / Baxalta India, 08 September 2015

CCI clears Baxter-Baxalta merger deal* CCI vide its order dated September 8, 2015 has approved the proposed transfer of Baxter India’s bioscience business and related assets

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Man Mohan Sharma
Vaish Associates Advocates (New Delhi)

India 263 contributions 41154 visits

Quotation

Man Mohan Sharma, The Indian Competition Authority clears structural separation of global pharmaceutical company’s bioscience business into separate new pharmaceutical company (Baxter India / Baxalta India), 8 September 2015, e-Competitions Pharma & Mergers, Art. N° 87760

Visites 126